New advances in synthetic biology uncovers lucrative investment opportunities for advisors. Sponsored by one of Novo Nordisk’s global research groups, a team of scientists recently installed one of the largest biosynthetic pathways––a series of biochemical reactions that occur inside an organism––into a strain of brewer’s yeast, Simon Barnett, ARK Invest’s director of research, life sciences, [...] The post ARKG Offers Exposure to Advancements in Synthetic Biology appeared first on ETF Trends .